1. Home

Accreditation & Credit Designation Statements

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the AATOD and the American Society of Addiction Medicine. The American Society of Addiction Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

The American Society of Addiction Medicine designates this live activity for a maximum of 36.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacy

This activity will offer 36.75 pharmacy contact hours (36.75 CEUs). Pharmacists will be asked to provide identifying information (e-Profile ID and DOB in MMDD format) in order to receive credit and allow reporting to CPE Monitor. (UAN: JA0000141-9999-24-057-L01)

PAs

ASAM has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 36.75 AAPA Category 1 CME credits.

Interprofessional Continuing Education (IPCE) Credits

This activity was planned by and for the healthcare team, and learners will receive 36.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

Disclosure Information

In accordance with the disclosure policies of ASAM and Joint Accreditation, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all accredited continuing education activities. These policies include identifying and mitigating all relevant financial relationships with ineligible companies for those involved in the creation and dissemination of accredited continuing education.

The following speakers have relevant financial relationships:

1. Frances Levin, MD (speaker): Aelis Pharmaceuticals – Other Research Support
2. Marianthi Markatou, PhD (speaker): Gilead – Grant recipient, Advisor
3. Alice Deschenau, MD, PhD (speaker): Camurus – Clinical Trial Investigator, Consultant
4. Kevin Sevarino, MD, PhD (speaker): GlaxoSmithKline – Shareholder
5. Jeffrey DeVido, MD, MTS, FASAM, FAPA (speaker): Merck – Shareholder; Phillip Morris/Altria – Shareholder
6. Kenneth Stoller, MD (speaker): Berkshire Biomedical – Consultant, Advisory Board; Indivior: Consultant, Advisory Board; CARI Health – Consultant, Advisory Board
7. Maurice Dematteis, MD, PhD (speaker): Accord Healthcare – Speaker honoraria; Camurus – Clinical Trial Investigator, Consultant, Speaker Honoraria; Indivior – Consultant, Speaker Honoraria
8. Boatemaa Nitri-Reid, JD, MPH (speaker): Gilead Sciences – Speaker Honoraria

All other planners, speakers, and staff have no relevant financial relationships.

All relevant financial relationships have been identified and mitigated.